nialamide has been researched along with Malignant Carcinoid Syndrome in 1 studies
Nialamide: An MAO inhibitor that is used as an antidepressive agent.
Malignant Carcinoid Syndrome: A symptom complex associated with CARCINOID TUMOR and characterized by attacks of severe flushing of the skin, diarrheal watery stools, bronchoconstriction, sudden drops in blood pressure, edema, and ascites. The carcinoid tumors are usually located in the gastrointestinal tract and metastasize to the liver. Symptoms are caused by tumor secretion of serotonin, prostaglandins, and other biologically active substances. Cardiac manifestations constitute CARCINOID HEART DISEASE. (Dorland, 27th ed; Stedman, 25th ed)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| HERMAN, Z | 1 |
1 other study available for nialamide and Malignant Carcinoid Syndrome
| Article | Year |
|---|---|
[EFFECT OF NIAMIDE ON THE BLOOD LEVEL 5-HYDROXYTRYPTAMINE AND ON THE URINARY EXCRETION OF 5-HYDROXYINDOLACETIC ACID IN PATIENTS WITH MALIGNANT CARCINOID SYNDROME].
Topics: Blood; Humans; Hydroxyindoleacetic Acid; Indoleacetic Acids; Malignant Carcinoid Syndrome; Nialamide | 1964 |